OSSK-674842

CAS No. 2054944-80-6

OSSK-674842( OSSK-2 | OSSK 674842 )

Catalog No. M13188 CAS No. 2054944-80-6

A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    OSSK-674842
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.
  • Description
    A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM; potentially serves as lead compound for development of new drugs for the treatment of cystic fibrosis.Cystic Fibrosis Preclinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    OSSK-2 | OSSK 674842
  • Pathway
    Apoptosis
  • Target
    CFTR
  • Recptor
    CFTR
  • Research Area
    Other Indications
  • Indication
    Fibrosis

Chemical Information

  • CAS Number
    2054944-80-6
  • Formula Weight
    457.122
  • Molecular Formula
    C16H15Br2N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(N/N=C/C(C=C(Br)C(O)=C1Br)=C1O)CNC2=CC=C(C)C=C2
  • Chemical Name
    (E)-N'-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cui G, et al. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L192-207.
molnova catalog
related products
  • Icenticaftor

    Icenticaftor is an orally active potentiator of?CFTR channel.

  • Astressin 2B

    Potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist (IC50 values are 1.3 and > 500 nM for CRF2 and CRF1 respectively). Antagonizes CRF2-mediated inhibition of gastric emptying.

  • Glucosamine

    Glucosamine is commonly used as a treatment for osteoarthritis, although its acceptance as a medical therapy varies.